October 29, 2026

FDA, CMS target gene therapy barriers

FDA and CMS initiatives aim to simplify gene therapy approvals and expand access to treatments for rare diseases.

MDSpire News

October 27, 2026

FDA expands talazoparib use in prostate cancer

The combination with enzalutamide reduced the risk of radiographic progression or death by 52% .

MDSpire News

October 26, 2026

Vampire bats may link Chagas cycles

Molecular screening detected Trypanosoma cruzi in 42% of sampled bats in northern Belize, raising questions about their role in parasite transmission.

MDSpire News

October 23, 2026

FDA raises TMB threshold for pembrolizumab

Traditional approval narrows eligibility for previously treated solid tumors after efficacy was not confirmed at lower biomarker levels.

MDSpire News

October 22, 2026

Medical Oddities: When puberty arrives at 4 months old

A genetic mystery, hearts in space, midnight munchies, and tea with muscle power are in the lineup this week.

MDSpire News

October 05, 2026

Gene may signal declining hair tensile resistance

Lower cortical disulfide bonding accompanied reduced tensile resistance with age, while follicular analyses identified COCH as a candidate molecular marker.

MDSpire News

September 24, 2026

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

MDSpire News

September 09, 2026

FDA expands sevabertinib approval in NSCLC

SOHO-01 data showed a 75% confirmed objective response rate among 69 patients without previous systemic therapy.

MDSpire News

September 08, 2026

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.

MDSpire News

September 04, 2026

Biomarker may flag early pregnancy risk

A protein was linked experimentally to trophoblast invasion.

MDSpire News